Blood markers could transform liver cancer surveillance

NCT ID NCT05148572

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study follows people with liver cancer who are scheduled for surgery, measuring tiny molecules called microRNAs in their blood before and after the operation. The goal is to find patterns that could signal whether the cancer has come back. Researchers will also look at gut bacteria and other substances in urine and blood to build a more complete picture. If these markers prove reliable, they might one day replace or improve current screening methods, which miss many early-stage liver cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test that detects liver cancer earlier and predicts recurrence after surgery.
What could go wrong
This is an observational study with only 101 participants, so findings may not apply to all patients. The biomarkers need further validation before they can be used in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Changi General Hospital

    Singapore, 529889, Singapore

  • National Cancer Centre Singapore

    Singapore, 168583, Singapore

  • National University Hospital

    Singapore, 119228, Singapore

  • Sengkang General Hospital

    Singapore, 544886, Singapore

  • Singapore General Hospital

    Singapore, 169608, Singapore

  • Tan Tock Seng Hospital

    Singapore, 308433, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.